IMTXImmatics N.V.

Healthcare
$7.43+11% 1Y

The financials

Immatics N.V. by the numbers

Immatics N.V. income statement, H2 2025 against the same quarter a year earlier
Income statementH2 2025Q2 2024Change
Operating income−€94M−€27Mn/a
Net income−€86M−€18Mn/a
Diluted EPS−€0.70−€0.17n/a

Biotechnology

Ranks #185 of 196 by RyuScore

Compare peers
COAG+2.5%
Hemab Therapeutics Holdings, Inc.
AVLN-0.31%
Avalyn Pharma Inc.
JBIO+1.9%
Jade Biosciences, Inc.
ORIC-0.08%
Oric Pharmaceuticals, Inc.
SVRA+1.7%
Savara Inc.
OMER+3.7%
OMEROS CORP